Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Establishment of different plasmid only-based reverse genetics systems for the recovery of African horse sickness virus

Andelé M. Conradie a, Liesel Stassen a, Henk Huismans b, Christiaan A. Potgieter c,d, Jacques Theron a,*

a Department of Microbiology and Plant Pathology, University of Pretoria, Pretoria 0002, South Africa
b Department of Genetics, University of Pretoria, Pretoria 0002, South Africa
c Deltamune (Pty) Ltd., Lyttelton, Centurion, South Africa
d Department of Biochemistry, Centre for Human Metabonomics, North-West University, Potchefstroom, South Africa

Article info
Article history:
Received 30 May 2016
Returned to author for revisions
5 July 2016
Accepted 6 July 2016
Available online 19 September 2016

Keywords:
African horse sickness virus
Orbivirus
Reverse genetics
dsRNA
Reoviridae
Virus rescue
T7 RNA polymerase
Reassortment

Abstract

In an effort to simplify and expand the utility of African horse sickness virus (AHSV) reverse genetics, different plasmid-based reverse genetics systems were developed. Plasmids containing cDNAs corresponding to each of the full-length double-stranded RNA genome segments of AHSV-4 under control of a T7 RNA polymerase promoter were co-transfected in cells expressing T7 RNA polymerase, and infectious AHSV-4 was recovered. This reverse genetics system was improved by reducing the required plasmids from 10 to five and resulted in enhanced virus recovery. Subsequently, a T7 RNA polymerase expression cassette was incorporated into one of the AHSV-4 rescue plasmids. This modified 5-plasmid set enabled virus recovery in BSR or L929 cells, thus offering the possibility to generate AHSV-4 in any cell line. Moreover, mutant and cross-serotype reassortant viruses were recovered. These plasmid DNA-based reverse genetics systems thus offer new possibilities for investigating AHSV biology and development of designer AHSV vaccine strains.

© 2016 Elsevier Inc. All rights reserved.

1. Introduction

African horse sickness (AHS), of which African horse sickness virus (AHSV) is the causative agent, is one of the most lethal systemic diseases of horses with a mortality rate in naïve animals up to 95% (Stassen et al., 2014). The virus is transmitted primarily by certain species of biting midges in the genus Culicoides, which become infected after taking a blood meal from an infected viraemic host (Mellor et al., 2000; Venter et al., 2009). Although AHS is endemic in sub-Saharan Africa, outbreaks with devastating effects have occurred in North Africa, the Middle East, the Arabian Peninsula and southern Europe (Howell, 1960; Rafyi, 1961; Diaz Montilla and Panos Marti, 1967; Lubroth, 1988; Rodriguez et al., 1992; Portas et al., 1999). Different factors such as climate change (Purse et al., 2008; Tabachnick, 2010) and increased international trade and movement of animals (MacLachlan and Guthrie, 2010; Martinez-Lopez et al., 2011) have raised concerns that AHSV may be re-introduced in European countries. Due to the economic impact of disease outbreaks, severity of disease in horses, and its capacity for sudden and rapid expansion, AHS is listed by the World Organization for Animal Health (OIE) as a notifiable equine disease.

AHSV is a member of the genus Orbivirus within the family Reoviridae. Like other members of this genus, AHSV is non-enveloped and has a complex capsid structure (Manole et al., 2012). The virion is comprised of two concentric protein shells surrounding the genome of 10 linear segments of double-stranded (ds) RNA, which are designated from segment 1 (S1) to S10 in decreasing order of size (Bremer et al., 1990). The outer capsid comprises two proteins, VP2 and VP5, which together form a continuous layer that covers the inner capsid or core. The core particle is composed of two major (VP3 and VP7) and three minor (VP1, VP4 and VP6) proteins, in addition to the dsRNA genome (Manole et al., 2012). The outer capsid proteins are removed during cell entry and transcriptionally active core particles are released into the cytosol where virus replication occurs (Forzan et al., 2007). Within the core particle, each of the dsRNA genome segments are repeatedly transcribed by the core-associated enzymes VP1 (RNA-dependant RNA polymerase), VP4 (capping-enzyme) and VP6 (helicase), resulting in extrusion of newly synthesized capped viral single-stranded RNA (ssRNA). The extruded positive-sense transcripts have the dual function of serving as templates for the synthesis of
viral proteins and for negative-sense RNA synthesis during dsRNA replication (Mertens and Diprose, 2004; Patel and Roy, 2014). In addition to the structural proteins, other AHSV-encoded proteins (NS1, NS2, NS3 and NS4) are also produced in infected cells where they are thought to be involved in virus replication, morphogenesis and release of progeny virus particles (Uitenweerde et al., 1995; van Staden et al., 1995; Maree and Huismans, 1997; Zwart et al., 2015). Although the veterinary (Guthrie, 2007; Clict and Penrith, 2010) and vaccine-related aspects of AHSV have received some attention (Scanlen et al., 2002; Guthrie et al., 2009; Alberca et al., 2014), AHSV replication and the role of individual viral proteins in this process, as well as AHSV-host cell interactions remain largely uncharacterized.

A reverse genetics system to engineer viable virus containing targeted sequence modifications has become an essential tool for the molecular dissection of viral gene products, studies regarding viral replication and pathogenesis, and for the development of vaccines. The development of a reverse genetics system for the Reoviridae family has lagged behind that of other RNA virus families due to technical complexities associated with the manipulation of multi-segmented dsRNA genomes (Kotani and Tani-guchi, 2013; Trask et al., 2013). Nevertheless, in recent years, reverse genetics systems have been developed for rotavirus (genus Rotavirus), reoviruses (genus Orthoreovirus), as well as AHSV, bluetongue virus (BTV) and epizootic haemorrhagic disease virus (EHDV) (genus Orbivirus) (Komoto et al., 2006; Kobayashi et al., 2007; Boyce et al., 2008; Kaname et al., 2013; Vermaak et al., 2015; Yang et al., 2015). For rotavirus, single gene replacement systems have been established for reoviruses and orbiviruses. AHSV, BTV and EHDV can be recovered by the transfection of in vitro-transcribed and capped RNAs into permissive cell lines (Boyce et al., 2008; Vermaak et al., 2015) and, more recently, for BTV (Prevot et al., 2015) and a fusogenic bat-borne orbivirus (Kawagishi et al., 2016). The development of reverse genetics has revolutionized the study of reoviruses (Dermody et al., 2013) and BTV (Roy, 2013) by providing a powerful tool for investigating virus replication and disease.

Here, we report the development of a plasmid-only reverse genetics system for AHSV-4 that allows for recovery of the virus from 10 cDNA clones representing the viral genome. We subsequently improved the basic AHSV-4 reverse genetics system by consolidating the viral genome segment cDNAs into five plasmids, which permits more efficient virus recovery compared to the 10-plasmid system. Finally, we increased the flexibility of the 5-plasmid reverse genetics system by including a T7 RNA polymerase expression cassette onto the genetic backbone of the reverse genetics plasmid, thus liberating the rescue of viable virus from its dependence on T7 RNA polymerase-expressing cell lines. The performance of the reverse genetics systems were validated by recovery of mutant and directed cross-serotype reassortant viruses. The enhancements reported here represent a significant advance for the application of reverse genetics to the study of AHSV.

2. Results

2.1. Construction of reverse genetics plasmids

Previous work from our laboratory established a reverse genetics system for the prototype orbivirus, BTV, using a bacteriophage T7 RNA polymerase system, whereby infectious virus could be generated reproducibly entirely from cDNA clones (Prevot et al., 2015). In this study, we generated two reverse genetics plasmids, pJAD1 and pJAD2, as described under Materials and Methods. Both the pJAD1 and pJAD2 plasmids contain an identical transcription cassette, which was obtained from the pRG15 reverse genetics plasmid, and is flanked by newly introduced T7Te transcription terminators to prevent transcription into or out of the cloned DNA. Moreover, with a view to reducing the number of plasmids required for AHSV-4 recovery, unique restriction enzyme sites were also incorporated into the reverse genetics plasmids. In the case of pJAD1, unique Stul restriction sites flanking the transcription cassette was incorporated, as well as a unique Pmel restriction site adjacent to the downstream T7Te terminator. In the case of pJAD2, unique Pmel restriction sites that flank the T7Te terminator sequences were incorporated (Fig. 1).

2.2. Plasmid-based reverse genetics of AHSV-4

To generate AHSV-4 from cloned cDNA, plasmids encoding each viral genome segment were engineered by incorporating cDNA copies of genome segments S1 through S5 into pJAD1 and cDNA copies of genome segments S6 through S10 into pJAD2. Each plasmid thus contains one full-length genome segment cDNA placed under control of the bacteriophage T7 RNA polymerase promoter and appended with the hepatitis delta virus (HDV) ribozyme at the 3’ terminus. After transcription with T7 RNA polymerase, these plasmids are anticipated to generate 10 full-length positive-sense RNAs, each containing native 5’- and 3’-ends (Fig. 2A).

The 10 AHSV-4 constructs were co-transfected into BSR-T7 cells, which constitutively express T7 RNA polymerase. The cells were harvested 5 days post-transfection, lysed and plaque assays were performed on BSR cells. Plaques were recovered from cells transfected with the 10 AHSV-4 cDNA plasmids, indicating the presence of replicating virus. In contrast, no plaques were observed in control, mock-transfected cells (Fig. 2B). To confirm virus recovery, individual plaques were picked, amplified in BSR cells and genomic dsRNA purified from infected cells was subsequently analysed on a non-denaturing polyacrylamide gel. The electrophoretic profile of plasmid-derived AHSV-4 was indistinguishable from that of wild-type AHSV-4 derived from cell infection (Fig. 2C).

To exclude the possibility that recovered AHSV-4 represents contamination by wild-type AHSV-4, a silent mutation (A to G at nucleotide 1010) resulting in the introduction of a unique Pmel site (Fig. 1) was introduced into the S5 genome segment by site-directed mutagenesis of the pJAD-S5 rescue plasmid. Since this change has not been observed in any reported AHSV S5 genome sequences, it thus serves as a signature for virus derived from plasmid-based rescue. The full-length S5 genome segment (1,748 kb) was amplified using RT-PCR of viral dsRNA extracted from BSR cells infected with either plasmid-derived AHSV-4 or wild-type AHSV-4. The S5 genome segment RT-PCR product derived from wild-type AHSV-4 was not digested with PstI, whereas the S5 product from plasmid-derived AHSV-4 produced the expected DNA fragments of 1012 and 736 bp upon digestion. The nucleotide sequence of the purified amplicons were also determined, the results of which confirmed the absence of the unique PstI restriction enzyme site in the S5 genome segment from plasmid-derived AHSV-4 (Fig. 2D).
2.3. Generation of a simplified reverse genetics system using five plasmids

Previous reports have indicated that a reduction in the number of plasmids required to rescue infectious virus may improve the efficiency of plasmid-based reverse genetics systems (Neumann et al., 2005; Zhang et al., 2011; Kobayashi et al., 2010). Thus, to reduce the number of plasmids required to rescue AHSV-4 by plasmid-based rescue, the AHSV-4 S6 through S10 genome segment transcription cassettes flanked by bidirectional T7 RNA polymerase promoters and restriction enzyme sites to facilitate cloning procedures are indicated.

A.M. Conradie et al. / Virology 499 (2016) 144–155

Fig. 1. Plasmid maps of the pJAD1 and pJAD2 reverse genetics vectors. In each of the pJAD1 and pJAD2 vectors (A), cloned cDNAs of the 10 full-length AHSV-4 dsRNA genome segments are flanked by a bacteriophage T7 RNA polymerase promoter and a HDV ribozyme sequence (B). Since the T7 RNA polymerase promoter directs transcription initiation from a juxtaposed guanosine residue and considering that all AHSV positive-sense RNAs are terminated with a guanosine, plasmid-derived transcripts are thus anticipated to possess the native 3′-end. Autocatalytic cleave of the nascent transcripts generates the native viral 3′-end. The transcription cassette in each reverse genetics vector is flanked by bidirectional T7 RNA polymerase promoters and restriction enzyme sites to facilitate cloning procedures are indicated.

Type AHSV-4 have similar replication kinetics, BSR cells were infected with the respective viruses at a MOI of 0.1 pfu/cell and virus titres were determined at different times post-infection. There was essentially no difference in growth kinetics, and the titres of the plasmid-derived AHSV-4 and wild-type AHSV-4 were virtually identical at all the time points tested (Fig. 2E).

Taken together, the data indicate that AHSV-4 can be recovered entirely from plasmid cDNA and that the plasmid-derived virus retained the properties of wild-type AHSV-4.

2.4. Generation of a modified 5-plasmid reverse genetics system that encodes both the AHSV-4 genome and T7 RNA polymerase

In both of the above reverse genetics systems, recovery of infectious AHSV-4 from plasmid DNA relies on the expression of T7 RNA polymerase within cells transfected with the AHSV-4 cDNA plasmids. Despite the success of both these approaches, they exclude the use of cells other than BSR-T7 cells for plasmid-based

respectively. To this end, a dual reverse genetics plasmid was constructed, designated pJAD(A1)-S2-S6, which contained transcription cassettes of the S2 and S6 genome segments from AHSV-1. BSR-T7 cells were co-transfected with 5 plasmids in which the wild-type pJAD-S2-S6 construct was substituted with the pJAD(A1)-S2-S6 construct. Reassortant viruses from randomly selected plaques were amplified in BSR cells, dsRNA extracted and the genotype of the recovered viruses was determined by electrophoresis of the dsRNA on a non-denaturing polyacrylamide gel. The electrophoresis pattern of a representative reassortant virus, AAVHSV-1VP2/VP5, clearly shows co-migration of the S2 genome segment dsRNA with that of AHSV-1, but it was not possible to distinguish the origin of the S6 genome segment (Fig. 4A). However, since genome segment S6 of AHSV-4, but not the S6 genome segment of AHSV-1, has a distinctive BamHI restriction site, the S6 genome segments of AHSV-4, AHSV-1 and the reassortant virus AAVHSV-1VP2/VP5 were amplified by RT-PCR and digested with BamHI. When analysed on an agarose gel, it was confirmed that the S6 genome segment of AHSV-4 was cleaved but not the S6 genome segments of AHSV-1 and the reassortant virus (Fig. 4B). The identity of the S2 and S6 genome segments of the reassortant virus as originating from AHSV-1 was furthermore confirmed by nucleotide sequencing of cDNA copies of the respective genome segments (data not shown). These results thus demonstrate the ability of the reverse genetics system to potentially generate reassortant viruses with any desired genetic combination between different AHSV strains or serotypes.

The electrophoresis pattern of a representative reassortant virus, AAVHSV-1VP2/VP5, clearly shows co-migration of the S2 genome segment dsRNA with that of AHSV-1, but it was not possible to distinguish the origin of the S6 genome segment (Fig. 4A). However, since genome segment S6 of AHSV-4, but not the S6 genome segment of AHSV-1, has a distinctive BamHI restriction site, the S6 genome segments of AHSV-4, AHSV-1 and the reassortant virus AAVHSV-1VP2/VP5 were amplified by RT-PCR and digested with BamHI. When analysed on an agarose gel, it was confirmed that the S6 genome segment of AHSV-4 was cleaved but not the S6 genome segments of AHSV-1 and the reassortant virus (Fig. 4B). The identity of the S2 and S6 genome segments of the reassortant virus as originating from AHSV-1 was furthermore confirmed by nucleotide sequencing of cDNA copies of the respective genome segments (data not shown). These results thus demonstrate the ability of the reverse genetics system to potentially generate reassortant viruses with any desired genetic combination between different AHSV strains or serotypes.

The identity of the S2 and S6 genome segments of the reassortant virus as originating from AHSV-1 was furthermore confirmed by nucleotide sequencing of cDNA copies of the respective genome segments (data not shown). These results thus demonstrate the ability of the reverse genetics system to potentially generate reassortant viruses with any desired genetic combination between different AHSV strains or serotypes.

The identity of the S2 and S6 genome segments of the reassortant virus as originating from AHSV-1 was furthermore confirmed by nucleotide sequencing of cDNA copies of the respective genome segments (data not shown). These results thus demonstrate the ability of the reverse genetics system to potentially generate reassortant viruses with any desired genetic combination between different AHSV strains or serotypes.
Fig. 2. Recovery of AHSV-4 from cDNA plasmids only. (A) Schematic of the approach. The 10 AHSV-4 constructs are co-transfected into BSR-T7 cells. Cytoplasmic transcription of the cloned cDNAs yield transcripts corresponding to viral positive-sense mRNAs with native 5' and 3' termini. Following 3–5 days of incubation, transfected cells are lysed and viable viruses are isolated by plaque assays on BSR cells. (B) Plaque assays of transfection cell lysates performed 5 days post-transfection (well 2). Mock-transfected cells were included as a control (well 1). (C) Electropherotypes of wild-type (WT) and plasmid-derived AHSV-4 (lanes 1 and 2). BSR cells were infected with wild-type AHSV-4 or rescued AHSV-4. At 72 h post-infection the viral dsRNA was extracted and electrophoresed in a non-denaturing polyacrylamide gel, followed by staining with ethidium bromide to visualize viral genome segments (S1–S10). (D) Digestion of the S5 genome segment RT-PCR products of wild-type AHSV-4 (WT) and plasmid-derived AHSV-4 (lanes 1 and 2) with PstI to confirm the presence of a novel mutation introduced into the S5 genome segment of plasmid-derived viruses. Size markers (M) are indicated in base pairs. The nucleotide sequence of the RT-PCR products was also determined and compared. Shown is the sequence chromatogram demonstrating the A→G substitution at nucleotide 1010. The creation of a novel PstI restriction site in the S5 genome segment of recombinant AHSV-4. (E) Growth kinetics of wild-type (wt) AHSV-4 and plasmid-derived AHSV-4 (rAHSV-4) in BSR cells. Cells were infected with virus at a MOI of 0.1 pfu/ml and incubated for the intervals shown. Virus titres in cell lysates were determined by plaque assays on BSR cells. The results are presented as the mean virus titres of three independent experiments and error bars indicate the standard deviation.
To increase the flexibility of AHSV-4 plasmid-based reverse genetics, we subsequently modified the 5-plasmid reverse genetics system by cloning a T7 RNA polymerase expression cassette, in which expression of the enzyme is under control of the constitutive cytomegalovirus (CMV) promoter, into the genetic backbone of the pJAD-S2-S6 reverse genetics vector. The derived plasmid was designated pJAD-S2-S6-T7pol and thus serves as a source of T7 RNA polymerase. Expression of the T7 RNA polymerase was confirmed by co-transfection of BSR cells with the pJAD-S2-S6-T7pol plasmid and a pJet-mKalama1 reporter plasmid, in which expression of the mKalama1 fluorescent protein is under transcriptional control of a T7 RNA polymerase promoter. Examination of the transfected cells at 16 h post-transfection by confocal microscopy indicated that, in contrast to mock-transfected cells, cells transfected with both plasmids fluoresced blue and thus confirmed expression of the plasmid-encoded T7 RNA polymerase (Supplementary Fig. S1).

To determine whether the modified 5-plasmid system allows recovery of AHSV-4, monolayers of BSR and L929 cells were co-transfected with the 5 plasmids encoding the AHSV-4 genome and T7 RNA polymerase (Fig. 5A). The cells were harvested at 3 days post-transfection, lysed and plaque assays were performed in BSR.

Fig. 3. Improved plasmid-based reverse genetics system for AHSV-4. (A) Two genome segment transcription cassettes encoding AHSV-4 cDNA flanked by the T7 RNA polymerase promoter and HDV ribozyme sequences were combined into a single plasmid, creating 5 plasmids encoding the viral genome. The procedure for AHSV-4 recovery is near identical to that for the 10-plasmid system, except that BSR-T7 cells are co-transfected with the 5 plasmids. (B) Plaque assays of transfection cell lysates performed 3 days post-transfection (well 2). Mock-transfected cells were included as a control (well 1). (C) Electropherotypes of wild-type (WT) and plasmid-derived AHSV-4 (lanes 1 and 2). The viral dsRNA was extracted from infected BSR cells at 72 h post-infection, separated on a non-denaturing polyacrylamide gel and visualized by staining with ethidium bromide. The genome segments (S1–S10) are indicated. (D) Digestion of the S5 genome segment RT-PCR products of wild-type AHSV-4 (WT) and plasmid-derived AHSV-4 (lanes 1 and 2) using PstI to confirm the presence of the signature mutation in the S5 genome segment as a genetic marker for viruses rescued from plasmid cDNA. Size markers (M) in base pairs are indicated.
or L929 cells. In contrast to mock-transfected cells, plaques were recovered from the different cells transfected with the modified 5-plasmid set (Fig. 5B). At different time points post-transfection, viral titres in cell culture supernatants were also determined by plaque assays. The results showed that the titres of virus recovered following transfection of BSR and L929 cells with the modified 5-plasmid set increased over time, albeit that the titres of virus recovered in L929 cells were consistently lower than that in BSR cells (Fig. 5C). To confirm that AHSV-4 was indeed recovered following plasmid transfection, the recovered viruses were propagated in BSR and L929 cells, viral dsRNAs were extracted and analysed by non-denaturing polyacrylamide gel electrophoresis. The profiles of viral dsRNAs from wild-type AHSV-4 as well as AHSV-4 recovered with the modified 5-plasmid system using BSR and L929 cells, were identical (Fig. 5D). Furthermore, both of the plasmid-derived AHSV-4 retained the PstI restriction site in their S5 genome segments as a rescue-specific marker, thus confirming that the recovered AHSV-4 originated from plasmid DNA (data not shown). These results provide evidence that the modified 5-plasmid reverse genetics system can be used to recover AHSV-4 in cells that have not been engineered to express T7 RNA polymerase.

2.5. Recovery efficiencies of the different plasmid-based reverse genetics systems

To compare the efficiencies of AHSV-4 recovery between the 10-plasmid, 5-plasmid and modified 5-plasmid reverse genetics systems, monolayers of BSR-T7 or BSR cells were co-transfected with the appropriate plasmid sets as indicated above. The virus titres in the culture supernatant were determined at different time points post-transfection by plaque assay on BSR cells.

For each of the reverse genetics systems, the viral titre in the supernatant of transfected cells was below the limit of detection at 12 h post-transfection. However, the titre of recovered virus increased over time and maximal yields of virus were recovered at 5 days post-transfection, but significant yields were detected at 3 days post-transfection. The mean titres at days 3 and 5 post-transfection were approximately 51 and 2 \times 10^3 pfu/ml, respectively, when BSR-T7 cells were transfected with the 10-plasmid system, whereas the virus yield using the 5-plasmid system determined at the same time points was approximately \(4 \times 10^2\) and \(3 \times 10^3\) pfu/ml, respectively. Virus yield was also high in the BSR cells co-transfected with the modified 5-plasmid system, with approximately \(0.9 \times 10^2\) and \(5 \times 10^2\) pfu/ml estimated at days 3 and 5 post-transfection, respectively (Fig. 6). From this data we conclude that AHSV-4 can be recovered using each of the developed reverse genetics systems and that reduction in plasmid number substantially improves rescue efficiency.

3. Discussion

Amongst the orbiviruses, bluetongue virus (BTV) has been studied the most extensively and thus serves as a model system for the distantly related AHSV. Despite similarities in their overall morphology, coding strategy and virus replication cycle, AHSV is, however, significantly different from BTV at both the genetic and structural levels and in the proteins it encodes (Kaname et al., 2013). Moreover, AHSV causes disease in horses and its pathogenesis is different from that caused by BTV infections in sheep and cattle (Coetzer and Guthrie, 2004; MacLachlan et al., 2009). To address this imbalance, attempts have been made to study the structure-function relationships of individual AHSV proteins through a strategy of mutagenesis and re-expression of the proteins in heterologous hosts (Uitenweerde et al., 1995; Maree and Huismans, 1997; van Nierkerk et al., 2001; de Waal and Huismans, 2005; Stassen et al., 2011; Bekker et al., 2014). However, a definitive role for many of these proteins in the context of a replicating virus remains unresolved. Consequently, the purpose of this study was to establish a reverse genetics system for the recovery of recombinant AHSV based entirely on cloned copies of the viral genome and, once established, to introduce improvements to the system that will expand the utility of reverse genetics for studies on AHSV biology.

During the development of reverse genetics systems for different RNA viruses, instability of cloned cDNA sequences in Escherichia coli have been reported for coronaviruses (Casais et al., 2001; Yount et al., 2000; Thiel et al., 2001), flaviviruses (Ward and
Fig. 5. Plasmid-based AHSV-4 reverse genetics system driven by a plasmid-encoded T7 RNA polymerase. (A) Schematic of the experimental strategy. A monolayer of BSR or L929 cells is co-transfected with a modified 5-plasmid set, in which the T7 RNA polymerase expression cassette is incorporated into the genetic backbone of the pJAD-S2-S6 reverse genetics plasmid to yield pJAD-S2-S6-T7pol. In cells co-transfected with the 5 plasmids, T7 RNA polymerase is expressed under control of a CMV promoter, which induces expression of transcripts corresponding to the native AHSV-4 positive-sense transcripts from the plasmids. After incubation for 3 days, recombinant viruses are recovered by plaque assays of the transfection cell lysates on BSR cells. (B) Plaque formation by recovered AHSV-4 viruses generated with the modified 5-plasmid reverse genetics system using BSR and L929 cells, as indicated in the figure. Mock-transfected cells were included as controls. (C) Comparison of virus recovery with the modified 5-plasmid system using BSR and L929 cells. Virus titres in supernatants of co-transfected BSR or L929 cells were determined at different time post-transfection by plaque assays on BSR cells. The results are presented as the mean titres of three independent experiments and error bars indicate the standard deviation. (D) Electrophoretotypes of the recovered viruses obtained by electrophoresis of viral dsRNA from wild-type (WT) AHSV-4 and dsRNAs obtained from recombinant AHSV-4 viruses recovered with the modified 5-plasmid system in BSR cells (lane 1) and L929 cells (lane 2). The non-denaturing polyacrylamide gel was stained with ethidium bromide to visualize the viral genome segments (S1–S10).
Davidson, 2008; Pu et al., 2011) and influenza virus (Zhou et al., 2011). Likewise, we occasionally found that cDNA copies of selected AHSV-4 genome segments, especially S3, were prone to deletions and rearrangements when cloned into the previously constructed pRG15 reverse genetics plasmid and cultured in E. coli. Although the reasons for this phenomenon were not investigated, such instability of cloned DNA sequences may be caused by different factors, including long repeat sequences, secondary and tertiary structures, the presence of active E. coli-like promoter sequences within the insert and the generation of toxic proteins (Godiska et al., 2010; Pu et al., 2011). Based on previous reports indicating that the stability of inserts in circular vectors can be increased by the use of transcriptional terminators (Godiska, 2005; Zhou et al., 2011), we thus incorporated bidirectional T7Ter terminators flanking the T7 RNA polymerase transcription cassettes present in the pJAD reverse genetics vectors. The successful cloning of cDNA copies of the AHSV-4 genome segments into the pJAD vectors and their stable maintenance using standard protocols suggest that the backbone of these vectors may provide enhanced stability for unstable AHSV-4 virus genome segments.

The initial AHSV-4 reverse genetics system developed here consists of 10 plasmids, each containing a full-length cDNA copy of single AHSV-4 genome segments flanked by T7 RNA polymerase promoter and HDV ribozyme sequences. These plasmids are presumed to generate 10 transcripts corresponding to native non-sense RNAs that serve as templates for translation and dsRNA replication. The AHSV-4 replication cycle is initiated by transfection of the 10 plasmids encoding the viral genome into cells expressing T7 RNA polymerase. Using this system, we demonstrated production of AHSV-4 from the cloned cDNAs and showed that this 10-plasmid reverse genetics system permits the selective introduction of desired mutations into the viral genome without the need for a helper virus and selection system. The growth kinetics and genomic electrophoretic profiles were indistinguishable between plasmid-derived AHSV-4 and wild-type AHSV-4, indicating that the replication characteristics of the AHSV-4 generated from cloned cDNA reflect that of the wild-type AHSV-4.

It is interesting to note that contrary to current RNA-based reverse genetics systems that all depend on the use of capped synthetic transcripts (Boycie et al., 2008; Kaname et al., 2013; Vermaak et al., 2015; Yang et al., 2015), the RNAs transcribed in situ from the recombinant plasmids will not contain a 5′ cap. These uncapped transcripts can nevertheless functionally substitute for viral transcripts at all stages of the AHSV replication cycle, as evidenced by the recovery of viable AHSV-4. These results are in agreement with those reported for reoviruses (Kobayashi et al., 2007; Kawagishi et al., 2016) and BTV (Pretorius et al., 2015). It is plausible that the sustained synthesis of RNA transcripts in situ results in sufficient levels of expression to allow the assembly of core particles, which themselves are transcriptionally active (Vermaak et al., 2015), and thus lead to an amplification of gene transcription.

A second aim of this study was to improve the performance of the developed AHSV-4 reverse genetics system by increasing the efficiency of virus recovery. To accomplish this aim, we reduced the number of plasmids required to deliver the entire AHSV-4 genome into BSR-T7 cells from 10 to 5 by combining two genome segment transcription cassettes into a single plasmid. Compared to the 10-plasmid reverse genetics system, this 5-plasmid strategy enhanced the efficiency of virus recovery by reducing the time to virus isolation and supporting increased total yields. The efficiency of virus recovery may have been enhanced by different mechanisms. Firstly, there are fewer plasmids that need to be transfected into each cell, and thus there is a higher probability that a full set of viral RNAs will accumulate in a cell for initiation of replication. Secondly, it is possible that only a small fraction of transfected plasmids avoid degradation and remain intact for transcription. By decreasing the number of plasmids the probability that a single cell will contain all of the transcription cassettes in a sufficient number is enhanced. Thirdly, construction of transcription and translation of individual RNAs to the same intracellular micro-environment may greatly facilitate protein-protein and protein-RNA interactions required for virus recovery (Neumann et al., 2005; Kobayashi et al., 2010). The 5-plasmid AHSV-4 reverse genetics system was sufficiently robust to allow the recovery of a directed cross-serotype reassortant virus.

Technical complexities associated with the construction and manipulation of the dual reverse genetics plasmids may make their use less appealing. In this regard, the 10-plasmid reverse genetics system remains a useful alternative for demanding cloning tasks. For example, we generated the AHSV-1-VP2/VP5 reassortant virus by combining four AHSV-4 dual plasmids and a dual plasmid containing cDNA copies of the S2 and S6 genome segments from AHSV-1. However, the same reassortant virus was also recovered successfully by combining the four AHSV-4 dual vectors with two single reverse genetics plasmids, which contained cDNA copies of the S5 and S6 genome segments, respectively. The efficiency of virus recovery was slightly lower compared to the use of 5 dual plasmids and is likely due to a lower transfection efficiency associated with the requirement for an additional plasmid for transfection (data not shown). Such an approach may be useful to generate so-called “serotyped” vaccine strains in which the immunogenic outer capsid proteins are exchanged with those of other virus serotypes (van Gennip et al., 2012; Feenstra et al., 2014, 2015; van de Water et al., 2015). Thus, the single reverse genetics plasmids remain important adjucnts to the 5-plasmid reverse genetics system by enhancing flexibility with gains in efficiency.

Although both the 10- and 5-plasmid reverse genetics systems are sufficient for generating recombinant AHSV-4, it would be an advantage if the dependence of virus recovery on the use of BSR-T7 cells could be overcome. To this end, we have cloned a T7 RNA polymerase expression cassette onto the genetic backbone of the pJAD-S2-S6 dual reverse vector and subsequently demonstrated that AHSV-4 could be recovered in BSR and L929 cells following transfection of the cells with the modified 5-plasmid set. In these experiments, the titre of AHSV-4 recovered in L929 cells was lower than that of virus recovered in BSR cells. This difference in virus titres may be ascribed to the ability of L929 cells to produce interferons (Takano-Maruyama et al., 2006), whereas BSR and BSR-T7 cells lack an interferon response (Rieder et al., 2011). These findings nevertheless provide evidence that this alternative 5-plasmid reverse genetics system can be employed using cell lines that have not been engineered to express T7 RNA polymerase, and thus provides for a streamlined reverse genetics system for recovery of AHSV-4 in different cell lines.
In conclusion, we have established a basic reverse genetics system for AHSV-4 and made improvements to the system that increase the flexibility and efficiency of reverse genetics, and also allows for the recovery of AHSV-4 in cells that have not been engineered to express T7 RNA polymerase. These entirely plasmid-based reverse genetics systems opens new possibilities for investigating virus infection at the molecular level, including virus protein function, virus replication, host-virus-vector interactions and pathogenesis. Moreover, the ability to recover mutant and reassortant viruses indicates that these reverse genetics systems can be exploited to generate further recombinant viruses that could be potential live-attenuated vaccines.

4. Materials and methods

4.1. Cells and viruses

BSR cells (a clone of baby hamster kidney-21 cells) were cultured in Eagle's minimum essential medium (EMEM) supplemented with Earle's balanced salt solution (EBSS), 2 mM L-glutamine, 5% (v/v) foetal bovine serum (FBS), 1% (v/v) non-essential amino acids (NEAA), and antibiotics (10,000 U/ml of penicillin, 10,000 μg/ml of streptomycin, 25 μg/ml of amphotericin B) (HyClone). L929 (mouse fibroblast) cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% (v/v) FBS and antibiotics (100 U/ml of penicillin, 100 μg/ml of streptomycin) (Gibco). BSR-T7 cells, which stably express bacteriophage T7 RNA polymerase (Buchholz et al., 1999), were maintained in the same manner as BSR cells, except for the addition of 1 mg/ml of Geneticin (Invitrogen) with every second passage of the BSR-T7 cells. All mammalian cell lines were grown at 37 °C with 5% CO2.

AHSV serotypes 1 (AHSV-1) and 4 (AHSV-4) were used in this study. The origin of AHSV-4 has been described previously (van de Water et al., 2015) and is a live-attenuated vaccine strain (AHSV-4LP) that was obtained by attenuation of virulent AHSV HS32/62 through passage in suckling mice and BHK-21 cells, followed by selection of large plaques on Vero cells (Erasmus, 1972). For cell Table 1

| Oligonucleotide | Sequence (5’–3’) | Use and properties |
|-----------------|------------------|--------------------|
| iPCR F          | CACAACCCGGCCGCTTACAGACAGGCTGTG | Construction of pJAD1 and pJAD2; T7Te terminator sequences are underlined, StuI restriction sites are indicated in italics and Pmel restriction sites are indicated in bold |
| iPCR R          | GAACAACGCCGGCCTCAAAGGCGGTAATACGACTCACTATAGTT | |
| Cas1F           | AGGGCTCCTCCGGGCTTCTCGCGGATCTGGAAATTATAGCTACTAGTT | |
| Cas1R           | CGAAGGCTCCTCCGGGCTTCTCGCGGATCTGGAAATTATAGCTACTAGTT | |
| Cas2F           | AGGGCTCCTCCGGGCTTCTCGCGGATCTGGAAATTATAGCTACTAGTT | |
| Cas2R           | CGAAGGCTCCTCCGGGCTTCTCGCGGATCTGGAAATTATAGCTACTAGTT | |
| InvF            | GGCCGCGATCTGCCCAAGC | Linearization of pJAD1 and pJAD2 for cloning |
| InvR            | TATAGTGAGTCGTATTA | AHSV-4 genome segment-specific primers |
| S1F             | GTATTGACGGATGTCATACCG | |
| S1R             | GTAAGTGTTCGATCTGGGCG | |
| S2F             | GTAAATTACATGGCGCCG | |
| S2R             | GTATGTTAATCCTAGGACCAAC | |
| S3F             | GTTTATTTTTCGTGTGAACCTCAG | |
| S3R             | GTAAGTGAATCTTGCGCCC | |
| S4F             | GTATTAGATGGAACCTTACG | |
| S4R             | GTAAGGTTATGATTCGC | |
| S5F             | GTTAAACACTAGGGCTTTCG | |
| S5R             | GTAAGTGTTCGATCTGGC | |
| S6F             | GTATTTTTCGCAAGACCTAG | |
| S6R             | GTAAGTGTTTTCGGACCCAC | |
| S7F             | GTAATTCGTCATGTCATG | |
| S7R             | GTAAGTGTATCCGATGTAGCTT | |
| S8F             | GTTTAACATCCGGCTCCG | |
| S8R             | GTAAGTGTTCGATCTGGCG | |
| S9F             | GTTAAATACCTGTCATGTCATG | |
| S9R             | GTAAGGTTATGATGGAACCTTACG | |
| S10F            | GTTAATTTTCTCTGGAATTACCTACG | |
| S10R            | GTAAGTGTTATCCGGCCCAAC | |
| S5PstI-F        | GGGAATCTCGACGGCGAATTTTTAGT | AHSV-4 S5 mutagenic primers |
| S5PstI-R        | ACTAAAATGAGTCGTTCGCG | |
| 2.1F            | GTTAAATCTATGCGTCCGAG | AHSV-1 genome segment-specific primers |
| 2.1R            | GTAAGTGTTCGATCTGGGCG | |
| 6.1F            | GTTTATTTTTCGCAAGACCTAG | |
| 6.1R            | GTAAGTGTTCGATCTGGCG | |
| T7Bam-F         | GAgatccATGACCGATATTAACTCGGTAAGAAGACTCTTC | Amplification of T7 RNA polymerase coding region from E. coli BL21(DE3) cells; BamHI restriction sites indicated in lower case letters |
| T7Bam-R         | GCggatctCTACCGGCAACGCGGATCCTGATCTAGATGTCT | |
| CMV-F           | GCgtatctGCCGCGGAAAGAACAGCCTGGGCTTCA | Amplification of expression cassette from pcDNA-T7pol; EcoRI restriction sites indicated in lower case letters |
| CMF-R           | GCgtatctGCTGACATGCTATTGAGCTAGTTA | |
infections, BSR cell monolayers were rinsed twice with incomplete EMEM [lacking FBS and antibiotics] and then infected with virus at a multiplicity of infection (MOI) of 0.1 pfu/cell. Virus adsorptions were performed at 37 °C for 1 h, followed by incubation of the cell monolayers in complete EMEM for 72 h.

4.2. Construction of pJAD1 and pJAD2 reverse genetics vectors

The pJAD1 and pJAD2 reverse genetics vectors share the same pUC19 genetic backbone, which lacks the lacZ region inclusive of the multiple cloning site, and was prepared by an inverse PCR using pUC19 as template (GenBank accession no. M777892) together with primers iPCR-F and iPCR-R (Table 1). To construct pJAD1, a transcription cassette comprising a T7 RNA polymerase promoter, followed by two inverted BsmBI restriction enzyme sites, a hepatitis delta virus (HDV) ribozyme sequence and a T7 RNA polymerase terminator sequence, was PCR-amplified from plasmid pRG15 (Pretorius et al., 2015) using primers Cas1F and Cas1R (Table 1). The amplicon was phosphorylated using T4 Polynucleotide kinase (Thermo Scientific) and then blunt-end ligated to the modified pUC19 genetic backbone. A similar strategy was used to construct pJAD2, except that the transcription cassette was PCR-amplified from plasmid pRG15 with primers Cas2F and Cas2R (Table 1). The nucleotide sequence of the cloned insert DNAs was verified by automated sequencing procedures using the ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction kit (Perkin-Elmer Applied Biosystems). The pJAD1 and pJAD2 reverse genetics vectors thus harbour identical transcription cassettes flanked by bidirectional T7Te terminators (Reynolds et al., 1992; Reynolds and Chamberlin, 1992) and contain unique restriction enzyme sites (Stul and/or Pmel) to facilitate cloning procedures (Fig. 1).

4.3. Cloning of AHSV-4 cDNA into pJAD1 and pJAD2

Total RNA was extracted from BSR cells infected with AHSV-4 using the Nucleospin RNA II kit (Macherey-Nagel) and ssRNA was removed by precipitation with 2 M LiCl and centrifugation at 17,000g for 30 min at 4 °C. First-strand cDNA was synthesized from 3 μg of dsRNA using the RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo Scientific), and cDNA copies of the full-length AHSV-4 genome segments were amplified by PCR using genome segment-specific primer pairs (Table 1) and high-fidelity Velocity DNA polymerase (Bioline). The purified amplicons were phosphorylated and then blunt-end-ligated to the respective pJAD vectors that had been linearized by means of an inverse PCR using primers InvF and InvR (Table 1). These back-to-back primers were designed to flank the poorly digestible BsmBI cloning site present in the pJAD vectors and thus resulted in the amplification of the vector DNA excepting the cloning site between the two primers. cDNA copies of AHSV-4 genome segments S1 through S5 were ligated to the pJAD1 vector, and cDNA copies of genome segments S6 through S10 were ligated to the pJAD2 vector to generate pJAD-S1 through pJAD-S10. The sizes of the recombinant plasmids are provided in Supplementary Table S1. Plasmid pJAD-S5, encoding the entire AHSV-4 S5 genome segment, has a PstI restriction site as the upstream CMV promoter. Subsequently, pcDNA-T7pol was used as template together with primers CMV-F and CMV-R (Table 1), both of which harbour an EcoRI site, to PCR amplify the T7 RNA polymerase expression cassette. This cassette comprised the T7 RNA polymerase coding region flanked by the upstream CMV promoter sequence and the downstream bovine growth hormone poly (A) sequence. The amplification was digested with EcoRV and blunt-end cloned into the SspI site of plasmid pJAD-S2-S6 to yield pJAD-S2-S6-T7pol. The integrity of the cloned insert was verified by nucleotide sequencing.

4.4. Construction of consolidated AHSV-4 reverse genetics plasmids

Recombinant AHSV-4 generation from five plasmids was facilitated by combining two genome segment transcription cassettes flanked by T7Te terminators onto one plasmid. To this end, recombinant plasmids pJAD-S6 through pJAD-S10 were digested with Pmel, and the excised DNA fragments were blunt-end cloned into the Pmel site of pJAD-S1 through pJAD-5. The derived reverse genetics plasmids were named pJAD-S1-S8, pJAD-S2-S6, pJAD-S3-S7, pJAD-S4-S10 and pJAD-S5-S9 (Supplementary Table S1). The integrity of the recombinant plasmids was verified by nucleotide sequencing of the genome segment transcription cassettes present in each of the recombinant constructs.

4.5. Construction of pJAD-S2-S6-T7pol

To enable the recovery of recombinant AHSV-4 from plasmid DNA in cell lines that have not been engineered to express T7 RNA polymerase (GenBank Accession no. AM946981), an expression cassette encoding for T7 RNA polymerase was incorporated into the genetic backbone of the pJAD-S2-S6 rescue plasmid. The coding region of the T7 RNA polymerase gene was PCR-amplified with Phusion High-Fidelity DNA polymerase (Thermo Scientific) using chromosomal DNA from E. coli BL21(DE3) as template and primers T7Bam-F and T7Bam-R (Table 1), which both harbour a BamHI site. The purified amplicon was digested with BamHI and cloned into the BamHI site of the pcDNA3.1(+) mammalian expression vector (Invitrogen) to generate pcDNA-T7pol. The recombinant plasmid DNA was characterized by nucleotide sequencing to confirm that the insert DNA was cloned under transcriptional control of the cytomegalovirus (CMV) immediate-early promoter. Subsequently, pcDNA-T7pol was used as template together with primers CMV-F and CMV-R (Table 1), both of which harbour an EcoRV site, to PCR amplify the T7 RNA polymerase expression cassette. This cassette comprised the T7 RNA polymerase coding region flanked by the upstream CMV promoter sequence and the downstream bovine growth hormone poly (A) sequence. The amplicon was digested with EcoRV and blunt-end cloned into the SpeI site of plasmid pJAD-S2-S6 to yield pJAD-S2-S6-T7pol. The integrity of the cloned insert was verified by nucleotide sequencing.

4.6. Construction of plasmids for use in reassortant experiments

Using similar approaches to those described above, full-length cDNAs of AHSV-1 genome segments S2 and S6 were amplified by RT-PCR using viral dsRNA extracted from virus-infected cells as template. Segment-specific cDNAs were amplified by using primers 2.1F and 2.1R for S2, and primers 6.1F and 6.1R for S6 (Table 1). The amplified cDNA for the AHSV-1 S2 and S6 genome segments were cloned into pJAD1 and pJAD2, respectively, and the derived recombinant plasmids were designated pJAD(A1)-S2 and pJAD(A1)-S6. The integrity of the cloned cDNA in each of the plasmids was confirmed by nucleotide sequencing. The S6 genome segment transcription cassette flanked by T7Te terminators was recovered from pJAD(A1)-S6 by digestion with Pmel and cloned into Pmel-digested pJAD(A1)-S2 to generate plasmid pJAD(A1)-S2-S6.

4.7. Recovery of recombinant viruses from cloned cDNA

Plasmid DNA used in cell transfections was purified using the Genopure Plasmid Maxi kit (Roche Life Science) according to the manufacturer’s instructions. Monolayers of BSR-T7 cells at 70% confluency in 6-well tissue culture plates were co-transfected with plasmids representing the cloned AHSV-4 genome using TransIT-
LT1 Transfection Reagent (Mirus). Briefly, 7.5 µl of the transfection reagent was added to 250 µl of OptiMEM I Reduced Serum Medium (Life Technologies) and incubated at room temperature for 30 min. For co-transfection of the cells with the 10 recombinant pJAD plasmids, 250 ng of each plasmid was mixed in an Eppendorf tube and the plasmid DNA mixture was then added to the diluted transfection reagent. Following incubation at room temperature for 1 h, the transfection mixture was added to the BSR-T7 cells and OptiMEM I Reduced Serum Medium was added to a final volume of 3 ml. At 16 h post-incubation, the medium was replaced with complete EMEM. An identical protocol to that above was followed to recover recombinant AHSV-4 from BSR-T7 cells transfected with the 5-plasmid set, except that 500 ng of each plasmid was used. The same protocol was followed to generate a reassortant virus, except that the pJAD-S2-S6 plasmid was substituted with the pJAD (A1)-S2-S6 plasmid prior to transfection of the BSR-T7 cell monolayer. Recombinant AHSV-4 was likewise recovered in monolayers of BSR and L929 cells using the modified 5-plasmid reverse genetics system, except that BSR or L929 cells were co-transfected with 500 ng of each dual (pJAD-S1-S8, pJAD-S3-S7, pJAD-S4-S10 and pJAD-S5-S9) plasmid and 1 µg of the pJAD-S2-S6-T7pol plasmid, and the volume of the transfection reagent used was adjusted to 9 µl. Following 1 to 5 days of incubation, cells and medium were harvested, lysed and used in a plaque assay on BSR cells (Oellermann, 1970).

4.8. Characterization of plasmid-derived viruses

Viral dsRNAs were extracted from infected cells, electrophoresed on non-denaturing 10% polyacrylamide gels and visualized by ethidium bromide staining. To discriminate between wild-type and plasmid-derived AHSV-4, full-length cDNA products of the nucleotide sequence of the amplified S5 genome segments was also determined. To characterize reassortant viruses, cDNA was synthesized from the viral dsRNA and PCR amplification was performed using S2 and S6 genome segment-specific primer pairs for AHSV-1. The purified genome segment S6 PCR product was analysed by agarose gel electrophoresis following digestion with BamHI, and the nucleotide sequences of the S2 and S6 PCR products were also determined.

4.9. Growth kinetics

Confluent BSR cell monolayers in 6-well tissue culture plates were infected with either wild-type AHSV-4 or plasmid-derived AHSV-4 at a MOI of 0.1 pfu/cell. Virus adsorptions were performed at 37 °C for 1 h, after which the medium containing unbound virus was removed. The monolayers were washed once with serum-free EMEM, 2 ml of complete EMEM was added and incubation was continued. At different time intervals post-infection the cells and medium were harvested. The samples were passed through a 22G needle and subjected to low-speed centrifugation to pellet cell debris. The virus titres were subsequently determined by serial dilution and plaque assays on BSR cells.

4.10. Comparison of AHSV-4 recovery using different reverse genetics systems

Monolayers of BSR-T7 cells were co-transfected with the 10-plasmid or 5-plasmid reverse genetics constructs and BSR cells were co-transfected with the modified 5-plasmid set, as described above. Aliquots (1 ml) of the supernatant of transfected cells were collected and replaced with 1 ml fresh medium at 12 h, 3 days and 5 days post-transfection. Virus titres in the culture supernatants were determined by plaque assays on BSR cells.

4.11. Confocal microscopy

To confirm expression of the plasmid-encoded T7 RNA polymerase, BSR cell monolayers, grown on sterile glass coverslips in 6-well tissue culture plates, were co-transfected with pJAD-S2-S6-T7pol (2 µg) and the reporter plasmid pJET-mKalama1 (800 ng) sing Transit-LT1 Transfection Reagent (Mirus). In the reporter plasmid, the coding region of mKalama1 is under transcriptional control of a T7 RNA polymerase promoter. At 16 h post-transfection, the glass coverslips were removed and mounted onto glass slides, which were viewed with a Zeiss LSM S10 Meta confocal microscope. The images were captured with a Zeiss Axiovert Series 5 digital camera and analysed with Zeiss LSM Image Browser v.4.2.0.121.

Acknowledgements

This work was supported by the University of Pretoria’s Institutional Research Theme Programme (Grant AOU999), Poliomyelitis Research Foundation (Grant 13/02) and the Technology Innovation Agency (Grant TAHC12-00028). Graduate bursary (AMC) and postdoctoral fellowship (LS) support was received from the National Research Foundation (Grant 89187) and the Poliomyelitis Research Foundation.

Appendix A. Supplementary material

Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.virol.2016.07.010.

References

Alberca, B., Bachanek-Bankowska, K., Cabana, M., Calvo-Pinilla, E., Viaplana, E., Frost, L., Gubbins, S., Uruza, A., Mertens, P., Castillo-Olivares, J., 2014. Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge. Vaccine 32, 3670–3674. Bekker, S., Huismans, H., van Staden, V., 2014. Factors that affect the intracellular localization and trafficking of African horse sickness virus core protein, VP7. Virology 456–457, 279–291. Boyce, M., Cetina, C.C.P., Roy, P., 2008. Development of reverse genetics systems for bluetongue virus: recovery of infectious virus from synthetic RNA transcripts. J. Virol. 82, 8339–8348. Bremer, C.W., Huismans, H., van Dijk, A.A., 1990. Characterization and cloning of the African horse sickness virus genome. J. Gen. Virol. 71, 793–799. Buchholz, U.J., Finke, S., Conzelmann, K.-K., 1999. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73, 251–259. Casais, R., Volker, T., Siddell, S.G., Cavanagh, D., Britton, P., 2001. Reverse genetics system for the avian coronavirus infectious bronchitis virus. J. Virol. 75, 12359–12369. Clift, S.J., Penrhyn, M.L., 2010. Tissue and cell tropism of African horse sickness virus demonstrated by immunoperoxidase labeling in natural and experimental infection in horses in South Africa. Vet. Path. 47, 690–697. Coetzer, J.A.W., Guthrie, A., 2004. African horse sickness. In: Coetzer, J.A.W., Tustin, R.C. (Eds.), Infectious Diseases of Livestock, second edition Oxford University Press, South Africa, pp. 1231–1246. de Waal, P.J., Huismans, H., 2005. Characterization of the nucleic acid binding activity of inner core protein VP6 of African horse sickness virus. Arch. Virol. 150, 2037–2050. Demody, T.S., Parker, J.S.L., Sherry, B., 2013. Orthoreoviruses. In: Knipe, D.M., Howley, P.M. (Eds.), Fields Virology, sixth edition Lippincott & Wilkins, Philadelphia, pp. 1304–1346. Diaz Montilla, R., Panos Marti, P., 1967. Epidemiology of AHS in Spain. Bull. Int. Epizoot. 68, 705–714. Erasmus, B.J., 1972. The pathogenesis of African horse sickness. In: Proceedings of the Third International Conference on Equine Infectious Diseases. Kager, Basel, Switzerland, pp. 1–11. Feenstra, F., Marris-Veldhuis, M., Daus, F.J., Tacken, M.G., Moormann, R.J., van...
Gennip, L., van Rijn, P.A., 2014. VP2-serotype live-attenuated bluetongue virus without NS5/NS3a expression provides serotype-specific protection and en- ables DIVA. Vaccine 32, 7108–7114.

Feasta, F., Pap, J.S., Feasta, P., 2015. Application of bluetongue disabled in- fective single animal (DSA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2. Vaccine 33, 812–818.

Forzan, M., Marsh, M., Roy, P., 2007. Bluetongue virus entry into cells. J. Virol. 81, 10395–10427.

Godiska, R., 2005. Beyond pUC: vectors for cloning unstable DNA. First edition., pp. 55–76.

Godiska, R., Mead, D., Dhodda, V., Wu, C., Hochstein, R., Karsi, A., Usdin, K., Entezam, A., Ravin, N, 2010. Linear plasmid vector for cloning of repetitive or unstable sequences in Escherichia coli. Nucl. Acids Res. 38 (6), e68.

Guthrie, A.J., 2010. African horse sickness. In: Sellon, D.C., Long, M.T. (Eds.), Equine Pathology, pp. 57–76.

Guthrie, A.J., 2007. African horse sickness. In: Mellor, P.S., Boorman, J., Baylis, M. (Eds.), Infectious Diseases of Livestock, pp. 145–1432.

Guthrie, A.J., 2004. The bluetongue virus core: a nano-scale transcriptome. J. Virol. 78, 1077–1085.

Guthrie, A., 2007. African horse sickness. In: Oellermann, R.A., 1970. Plaque formation by African horsesickness virus and its replication in Vero cells. Arch. Virol. 14, 289–296.

Neumann, G., Fuji, K., Kino, Y., Kawaoka, Y., 2005. An improved reverse genetics based reverse genetics system for bluetongue virus. Virology 486, 71–77.

Guthrie, A.J., 2009. Reverse genetics and the study of dengue virus. J. Virol. 83, 9268–9274.

Guthrie, A.J., 2005. Beyond pUC: vectors for cloning unstable DNA, First edition., pp. 55–76.

Guthrie, A., Campuzano, E., 2013. Genetic engineering of rotaviruses by reverse gene recombination: lessons from studies of the Aicardi–Goutières syndrome. Retrovirology 10, 9.

Kawagishi, T., Antar, A.A.R., Boehme, K.W., Danthi, P., Eby, E.A., Guglielmi, K.M., Kaw, Y., Kawaoka, Y., 2011. Comparative analysis of flavivirus and Epizootic haemorrhagic disease virus differ in their single-stranded RNA- plus-strand synthesis. PLoS Pathog. 7, e1001321.

Kawahashi, T., Antar, A.A.R., Boehme, K.W., Danthi, P., Eby, E.A., Guglielmi, K.M., Kaw, Y., Kawaoka, Y., 2011. Comparative analysis of flavivirus and Epizootic haemorrhagic disease virus differ in their single-stranded RNA- plus-strand synthesis. PLoS Pathog. 7, e1001321.

Kawagishi, T., Antar, A.A.R., Boehme, K.W., Danthi, P., Eby, E.A., Guglielmi, K.M., Kaw, Y., Kawaoka, Y., 2011. Comparative analysis of flavivirus and Epizootic haemorrhagic disease virus differ in their single-stranded RNA- plus-strand synthesis. PLoS Pathog. 7, e1001321.

Kim, Y., Kwon, T.W., Lee, S.Y., Shin, J.H., Sung, K.Y., Lee, Y.S., Kwon, Y.T., 2011. Diversified genetic variation mechanisms drive evolution of bluetongue virus. Virol. J. 8, 143.

Kobayashi, T., Antar, A.A.R., Boehme, K.W., Danthi, P., Eby, E.A., Guglielmi, K.M., Kaw, Y., Kawaoka, Y., 2011. Comparative analysis of flavivirus and Epizootic haemorrhagic disease virus differ in their single-stranded RNA- plus-strand synthesis. PLoS Pathog. 7, e1001321.

Kobayashi, T., Antar, A.A.R., Boehme, K.W., Danthi, P., Eby, E.A., Guglielmi, K.M., Kaw, Y., Kawaoka, Y., 2011. Comparative analysis of flavivirus and Epizootic haemorrhagic disease virus differ in their single-stranded RNA- plus-strand synthesis. PLoS Pathog. 7, e1001321.

Kobayashi, T., Antar, A.A.R., Boehme, K.W., Danthi, P., Eby, E.A., Guglielmi, K.M., Kaw, Y., Kawaoka, Y., 2011. Comparative analysis of flavivirus and Epizootic haemorrhagic disease virus differ in their single-stranded RNA- plus-strand synthesis. PLoS Pathog. 7, e1001321.

Kobayashi, T., Antar, A.A.R., Boehme, K.W., Danthi, P., Eby, E.A., Guglielmi, K.M., Kaw, Y., Kawaoka, Y., 2011. Comparative analysis of flavivirus and Epizootic haemorrhagic disease virus differ in their single-stranded RNA- plus-strand synthesis. PLoS Pathog. 7, e1001321.

Kobayashi, T., Antar, A.A.R., Boehme, K.W., Danthi, P., Eby, E.A., Guglielmi, K.M., Kaw, Y., Kawaoka, Y., 2011. Comparative analysis of flavivirus and Epizootic haemorrhagic disease virus differ in their single-stranded RNA- plus-strand synthesis. PLoS Pathog. 7, e1001321.

Kobayashi, T., Antar, A.A.R., Boehme, K.W., Danthi, P., Eby, E.A., Guglielmi, K.M., Kaw, Y., Kawaoka, Y., 2011. Comparative analysis of flavivirus and Epizootic haemorrhagic disease virus differ in their single-stranded RNA- plus-strand synthesis. PLoS Pathog. 7, e1001321.

Kobayashi, T., Antar, A.A.R., Boehme, K.W., Danthi, P., Eby, E.A., Guglielmi, K.M., Kaw, Y., Kawaoka, Y., 2011. Comparative analysis of flavivirus and Epizootic haemorrhagic disease virus differ in their single-stranded RNA- plus-strand synthesis. PLoS Pathog. 7, e1001321.